The administration of AAS to increase muscle mass and strength is commonly found in treatment of chronic diseases. This includes HIV+, cancer, chronic renal failure, and others. As I demonstrate in the book, “Anabolic Steroids - A Question of Muscle: Human Subject Abuses in Anabolic Steroid Research,” the research supporting this treatment does not include the period after stopping AAS. I recognized this and sought to develop a treatment for anabolic steroid induced hypogonadism. After successfully developing a treatment, I began to develop programs aimed at individuals with chronic disease that would promote positive body composition changes but without the attendant hypogonadism after stopping AAS. The following is an example of one such patient. The initial (baseline) lab and body composition testing are done prior to initiation of AAS. [Note: The CBC changes on recheck were normal. For obvious reasons, I am not including the AAS schedule.] The final lab and body composition testing are upon the conclusion of the AIH protocol. AAS administration is for 12 weeks followed by the AIH protocol. The diet and exercise are tailored to the patient. The HPTA suffers no suppression. Significantly, the body composition changes include an increase in lean body mass from 62.3 to 71.4 kg (+9.1); a decrease in body fat from 22.1 to 14.4 kg (-7.7); a slight increase in total body weight from 88.1 to 89.5 kg (+1.4). Overall, these changes reflect a decrease in body fat from 26.2% to 16.7% (-9.5%).